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Abstract
Background
Phase III trials of long-acting injectable (LAI) PrEP, currently underway, have great potential
for expanding the menu of HIV prevention options. Imagining a future in which multiple PrEP
modalities are available to potential users of biomedical HIV prevention, we investigated
which factors might help direct a patient-physician shared-decision making process to opti-
mize the choice of biomedical HIV prevention method.
Methods
Participants (n = 105; ages 19–63; 46.7% men of color) were former participants in a PrEP
demonstration project and had taken daily oral PrEP for 12 months. Participants were
given information about LAI PrEP and asked whether they would be interested in switching
from oral to LAI PrEP. Participants were also asked about specific pros/cons of LAI PrEP,
PrEP attitudes and experiences, and personality factors.
Results
Two-thirds (66.7%) of current oral PrEP users would switch to LAI PrEP. Intention to
switch was associated with product-level and psychosocial factors. Attitudes towards
logistical factors (i.e. getting to regular clinic visits for recurring shots) featured more prom-
inently than factors related to the physical experience of PrEP modality (i.e., concerns
about injection pain) as motivators for switching. In a multivariate regression model, psy-
chosocial factors including the emotional burden of daily pill taking, deriving a sense of
responsibility from PrEP use, and self-identifying as an early adopter, were the strongest
predictors of switching.
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Conclusions
These data underscore the importance of attending not only to product-level factors, but
also to the logistical and psychological experience of prevention methods for users. Findings
have significant implications for the development of patient education materials and patient-
provider shared decision aids.
Introduction
Tenofovir-based oral PrEP is the only biomedical approach currently approved to prevent
HIV. Other ARV-based prevention modalities—including vaginal rings, microbicides, alter-
nate oral agents, injectables—are currently in clinical development, with the long-acting inte-
grase inhibitor Cabotegravir Long-Acting (Cab-LA) furthest along. With the prevention
efficacy of Cab-LA under investigation in a global study of men who have sex with men
(MSM) and transgender women who have sex with MSM [1], a series of sociobehavioral stud-
ies have begun assessing attitudes towards long-acting injectable PrEP (LAI-PrEP) among
gay men in the US and other settings [1–9]. These studies show variable enthusiasm for an
injectable PrEP product, with positive attitudes towards LAI PrEP (as measured by acceptabil-
ity, preference or willingness to use) ranging from 25.2% [3] to 80.0% [6]. This variability is
likely due to heterogeneity in study design, wording of survey questions, different explanation
of LAI-PrEP, and/or real differences between populations. However, taken together, these
studies do suggest that the addition of a second PrEP modality would likely attract PrEP-naïve
users for whom the daily oral pill was not acceptable and consequently increase overall PrEP
use [9]. While useful in establishing acceptability of attributes of a particular product-type at
the most basic level, clinical trials are limited in the depth with which they can collect data on
the acceptability of a specific biomedical prevention technology among potential users.
For this new biomedical prevention strategy to be effective, it is important to understand
not only interest in Cab-LA during clinical development, but also its likelihood of being
adopted by real users and the factors that might underlie decisions about uptake. People who
are already on oral PrEP present a particularly informative population in which to study this
question, as these individuals have experienced the physical and psychosocial benefits and
challenges of daily oral PrEP use first-hand. For example, they may have experienced a
decrease in anxiety around sex [10, 11], an increase in intimacy with partners [10, 12], an
increase in sexual satisfaction [10, 13], worry about missing doses [14, 15], changes in fre-
quency of condomless sex [10, 16, 17], infection with an STI [18], or increases in stigma related
to sexual practices and choices in HIV prevention methods [13, 19]. In addition, current oral
PrEP users understand the logistics of taking PrEP, including regular clinic visits [20], timely
pharmacy refills [21], storing of pills [22, 23], and integrating the medication into their rou-
tines and lifestyles [22, 23]. The experience of integrating oral PrEP into their daily lives allows
them to provide answers to questions about a hypothetical new injectable formulation of
PrEP, informed by real world practice. Some of these experiences may continue to exist with
the use of an injectable product, some may be overcome by its development, and some distinct
new experiences are likely to arise as well.
The goal of this study was to investigate specific factors that might help direct a patient-pro-
vider shared decision-making process to optimize the choice of biomedical HIV prevention
method. Such tools have been utilized in the contraceptive field [24–27] and our objective was
to generate preliminary data that could usefully differentiate between current oral PrEP users
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who would or would not switch to LAI-PrEP. Specifically, the study focused on product-
related and psychosocial factors that may impact implementation of LAI-PrEP. We tested
measures that we hypothesized would help us understand who would be a good candidate
for an intra-muscularly-injected versus an orally-administered PrEP product. Hypothesized
domains included: 1) product-related factors, such as the physical experience of the PrEP
modality and logistical features of administration; and 2) psychosocial factors, like agency and
control, psychosocial aspects of adherence, and self-identification as an early-adopter or risk
taker.
Materials and methods
Study population and procedures
Participants were recruited from among former participants of a PrEP demonstration project
in New York City (NIH RO1: MH106380). Eligible participants were assigned male sex at
birth, over age 18, had been prescribed PrEP in the context of the SPARK PrEP Demonstration
Project, and reported having taken PrEP for at least 12-months. All eligible participants of the
original study who had indicated interest in being contacted for future research participation
were contacted by research staff (n = 237). Of these, 72 (27%) never responded to our contact,
27 (11%) declined to participate, 32 (12%) scheduled a study visit but did not attend, and 106
(40%) completed a study visit. Those who completed study visits did not differ significantly
from those in the other three groups on age, race/ethnicity, education, income, or insurance
status. One participant left the majority of his survey blank, and was excluded from further
analysis, leaving a final analytic sample of 105.
Participants completed a Qualtrics-programmed survey on a computer during an in-person
visit at Hunter College and received $40 compensation upon completion. All participants
completed an informed consent process with study staff and signed a written consent form.
The study was reviewed and approved by the Human Research Protections Program at the
City University of New York (IRB file number 2015–0455).
Survey design and measurement
Participants were given the following written description of the “PrEP shot”:
“an anti-HIV medication that is made into an injection (shot) that can remain in the blood
for a long period of time. You take one month of daily pills to make sure you don’t have a
reaction to the medication. Then come to a clinic every three months to get two shots in the
buttocks by a medical provider.”
Following this description, participants completed self-report survey items. The survey
instrument included a series of close-ended and open-ended questions developed specifically
for this study, based on the research team’s experience investigating the use of daily oral PrEP
and injectable PrEP among users [28, 29] and clinical trial participants [30]. Because these
measures were developed for this project, and because few (if any) acceptability measures exist
specific to LAI PrEP, we have provided our complete list of measures in Table 1. We used four
types of items and response choice sets to measure participant attitudes, including: a) pro/con
judgements, in which participants read characteristics and were asked to rate the extent to
which each was a “pro” or a “con” of the shot compared to the PrEP pill; b) Polar or “A versus
B” items, in which participants are presented with two opposite statement and were asked to
rate themselves between them; c) Likert-type scale items, in which participants responded to
statements about injections and pills on a seven-point scale ranging from “very challenging” to
Intentions to switch from oral to injectable PrEP among oral PrEP users
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“very easy”; and d) classic Likert-scale items, in which participants responded to statements on
a seven-point scale ranging from “strongly agree” to “strongly disagree”. As demonstrated in
Table 1, measures were divided into “product-level” factors, including physical experience and
logistics/convenience and “psychosocial factors’, which included feelings of control, psychoso-
cial attitudes/preferences, and feelings about adherence.
Willingness to switch. After completing these survey measures, participants were asked:
“If the PrEP shot were FDA approved and available for the same cost as the daily PrEP pill,
how likely would you be to switch to the PrEP shot?” on a 5-point scale from 1, definitely
Table 1. Hypothesized predictors of LAI PrEP switch intentions.
Concepts Indicators Measures
A. Pro/Con Judgments. Participants indicate the extent to which each is a pro or a con of the PrEP shot on a 7-point scale, ranging from 1 (this is a pro of the shot) to 7
(this is a con of the shot).
Physical Experience Peri-injection pain I would be worried about pain during the shots
Injection blemish I would be worried that there would be a bump or a mark from the shots.
Post-injection pain I would be worried about pain in the days after the shot.
Logistics/
Convenience
Injection interval I would have to get two shots in the butt every 8–12 weeks.
Daily pill-taking I wouldn’t need to take a pill every day.
Adherence when
partying
I wouldn’t have to worry about remembering to take medications when I party.
Adherence when
traveling
I wouldn’t have to remember to bring pills with me when I sleep somewhere new or go on a trip.
Feeling of Control Logistical control I wouldn’t have control over starting and stopping the medication because it would be in my body for 8–12 weeks after
the shots.
Psychological control I would feel less in control of my HIV prevention because I’m not actively taking a pill daily
Reliability concerns I would be worried that the shot would stop working in my body and I wouldn’t know.
B. Polar items (A vs. B) items. Participants place themselves along a 7-point line, as described below.
Physical Experience Pain tolerance “I have a really low tolerance for pain or discomfort; feeling
bad can really ruin my day”
1 |- - -|
7
“I have a high tolerance for pain or discomfort;
if I feel bad, I just ignore it”
Injection tolerance “I hate getting shots and try to avoid them whenever
possible”
1 |- - -|
7
“Shots don’t bother me if I need them”
Pill aversion “I hate swallowing pills” 1 |- - -|
7
“I don’t mind swallowing pills”
Psychosocial factors Spontaneity “I’m a ‘creature of habit,’” 1 |- - -|
7
“I like to be as spontaneous as possible”
Routine preference “I like to have a set routine that I follow every day” 1 |- - -|
7
“I hate having a set routine; I like to be flexible”
Active prevention “I like to know that I’m doing something active to control
my HIV risk”
1 |- - -|
7
“I like having an HIV prevention strategy that I
never have to think about”
Protection consistency “I like an HIV prevention method that is active in my body
all the time so I’m always protected”
1 |- - -|
7
“I like an HIV prevention method that I use
only when I actually need it”
Early Adopter “I’m the kind of person who is always the first to try
something new”
1 |- - -|
7
“I’m the kind of person who is slow to try new
things”
C. Likert-scale judgments ranging from 1 (strongly disagree) to 7 (strongly agree)
Feelings about
adherence
Emotional burden of
daily pills
Taking PrEP pills every day feels like an emotional burden
Personal responsibility Taking PrEP pills every day makes me feel responsible
D. Likert-type scale judgments, ranging from 1 (very challenging) to 7 (very easy)
Logistics/
Convenience
Pill pick-up Picking up refills of PrEP pills
Shot schedule Returning to the clinic every 8–12 weeks to get your shots
Pill frequency Remembering to take a pill every day
Clinic visit interval Coming to the clinic for visits every 3 months
https://doi.org/10.1371/journal.pone.0200296.t001
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switch to 5, definitely not switch with mid-point “unsure”. Those who would definitely or
probably switch were categorized as “switchers”, those who were unsure, or would probably or
definitely not switch were categorized as “non-switchers”.
Demographic variables. As part of the survey, participants were asked to report their age,
race/ethnicity, sexual orientation, education, employment, and income. Additional items col-
lected information on living situation and partnership characteristics.
We also asked three open-ended questions to elicit more details on participants’ perspec-
tives on the relative pros and cons of the PrEP shot as compared to daily oral PrEP: (1) What
do you think is the biggest benefit or “pro” of the PrEP shot compared to the PrEP pill?; (2)
What do you think is the biggest drawback or “con” of the PrEP shot compared to the PrEP
pill?; (3) Please tell us a little bit about why you would or wouldn’t switch.
We included open-ended questions for several reasons. First, given the preliminary nature
of the constructs and measures we developed to capture them, we wanted participants to be
able to raise issues that we may not have previously considered and provide more depth to
their survey responses [31, 32]. Second, we anticipated that some items might lack variability
in responses due to the potential homogeneity in a cohort of early oral PrEP adopters. Such a
lack of variability may impact on the quantitative analysis and significance of findings; there-
fore, we included open-ended fields that would allow us to pick up common themes.
Across the three open questions, 97.5% of respondents provided answers. Text entered by
participants in response to the three open-ended questions was organized thematically around
the motivators and barriers to switching identified in the statistical analysis. One researcher
coded and categorized the data. Two other researchers reviewed the coding and final coding
was based on group discussion. Excerpts were chosen to provide a more detailed explanation
of the respondents’ answers to the survey items.
Statistical analysis
We first examined bivariate associations between the outcome (i.e., intention to switch) and
each of the predictor variables. Variables that were significant in bivariate testing (p< .10)
were entered into a multivariable logistic regression model. We report both bivariate and
adjusted odds ratios. All continuous measures were z-scored for ease of comparison across
measures with different scales; increases in odds are associated with standard deviation
increases in any given measure. Analysis was performed in SPSS 24.0.
Results
Intention to switch from oral to LAI-PrEP
The sample was largely gay (89.5%), ethnically diverse (46.7% non-white), and fairly well dis-
tributed in terms of education, income, and insurance status (Table 2). Almost 92% of the
sample (n = 96) were still taking PrEP. Two-thirds of the sample reported that they would defi-
nitely (36.2%) or probably (30.5%) switch from daily oral PrEP to LAI-PrEP. About one fifth
(21.0%) were unsure whether or not they would switch, a tenth (9.5%) would probably not
switch, and 3 out of 106 respondents (2.9%) would definitely not switch.
Factors associated with intention to switch
Intention to switch to LAI from oral PrEP was not associated with age, race/ethnicity, sexual
orientation, education, insurance status, factors related to partnership type, or whether or not
the participant was a current PrEP user. However, income was associated with intention to
switch; specifically those with moderate income ($30,000-$50,000) were more likely to
Intentions to switch from oral to injectable PrEP among oral PrEP users
PLOS ONE | https://doi.org/10.1371/journal.pone.0200296 July 19, 2018 5 / 14
Table 2. Sample characteristics (n = 105).
Demographics n (%)
Age
<30 40 (38.1)
> = 30 65 (61.9)
Race and ethnicity
Black 10 (9.5)
Latino/Hispanic 28 (26.7)
White 56 (53.3)
Multiracial 6 (5.7)
Other 5 (4.8)
Sexual orientation
Gay 94 (89.5)
Bisexual 7 (6.7)
Queer 4 (3.8)
Education
Less than 4-year college degree 33 (31.4)
4-year college degree or more 72 (68.6)
Employment
Full-time 62 (59.0)
Not full-time 43 (41.0)
Annual income
<$30,000 36 (34.3)
$30,000-$50,000 38 (36.2)
>$50,000 31 (29.5)
Insurance Status
Private Insurance 52(49.5)
Medicaid 25 (23.8)
Uninsured 21 (20.0)
Living status
Living alone 34 (32.4)
Not living alone 71 (67.6)
Do you have a partner at this time?
I am in a committed relationship 26 (24.8)
I have a boyfriend or a girlfriend 16 (15.2)
I am casually dating 21 (20.0)
I am single 42 (40.0)
Main partner on PrEP (n = 42)
Yes 15 (35.7)
No 27 (64.3)
Sexual relationship with main partner (n = 42)
Neither of us has sex with others, we are monogamous 14 (33.3)
We both have sex with others 21 (50.0)
Only I have sex with others 4 (9.5)
I have sex with others; I don’t know what my partner does 2 (4.8)
I don’t have sex with others; I don’t know what my partners does. 1 (2.4)
Current PrEP User 96 (91.4)
https://doi.org/10.1371/journal.pone.0200296.t002
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consider switching, compared to those who reported highest income (Table 3). Income was
included in the final model.
In bivariate analysis, intention to switch to LAI-PrEP was positively associated (p< .10)
with four product-level factors and five psychosocial factors (Table 3). Analysis of the qualita-
tive data allowed us to include illustrative quotes for the bivariate factors.
Product-level motivators and barriers to switching
Physical experience of product use. Among six items measuring aspects of the physical
experience of product use, four items did not show any association with the outcome: worries
about pain during the shots, general tolerance for pain or discomfort, worries about visible
marks on butt following the shot, and attitudes towards swallowing pills. In bivariate analysis,
respondents who self-identified as having high injection tolerance (i.e., not being bothered by
shots) had higher odds of switching (OR = 1.64), whereas those who were more concerned
about post-injection pain had lower odds of switching (OR = 0.57).
Among non-switchers, a negative “gut reaction” to needles was a common theme in the
qualitative responses, as captured in the following statements relating to needles and injection
pain: “Although I think it’s a nice option to choose between one or the other, I personally hate
needles!” (Hispanic, 25 years old, unsure). A 24-year-old Black participant reasoned that “the
Table 3. Factors associated with intention to switch from oral to injectable PrEP (n = 105).
OR 95% C.I. aOR 95% C.I.
Product level factors
Physical experience
Injection tolerance 1.64 (1.09, 2.47) 0.75 (0.30, 1.89)
Concerns about post-injection pain 0.57 (0.37, 0.90) 0.81 (0.36, 1.80)
Logistical/convenience
Injection interval is a con of the shots 0.30 (0.17, 0.54) 0.37 (0.15, 0.91)
Clinic visits for injections are difficult 0.37 (0.22, 0.60) 0.31 (0.11, 0.91)
Psychosocial level factors
Psychosocial aspects of adherence
Taking pills daily is an emotional burden 1.54† (0.92, 2.59) 13.71 (2.05, 91.86)
Agency/control
Taking PrEP pills every day makes me feel responsible 1.87 (1.20, 2.92) 4.72 (1.60, 13.96)
Not taking a pill every day would make me feel less in control of my HIV prevention 0.55 (0.35, 0.88) 0.42 (0.17,1.03)
I wouldn’t have control over starting and stopping the medication 0.56 (0.36, 0.88) 0.83 (0.35, 1.93)
Early adopter
Early adopter 2.88 (1.73, 4.81) 3.77 (1.37, 10.35)
Demographics
Income
Less than $30,000 2.42 (0.89, 6.59) 4.07 (0.63,26.11)
$30,000-$50,000 4.00 (1.40,11.44) 5.62 (1.01, 31.33)
More than $50,000 ref ref
Note.
†: p = .10
: p<0.05,
: p<0.01,
: p < .001.
https://doi.org/10.1371/journal.pone.0200296.t003
Intentions to switch from oral to injectable PrEP among oral PrEP users
PLOS ONE | https://doi.org/10.1371/journal.pone.0200296 July 19, 2018 7 / 14
fact that it’s likely a large needle that causes pain in pretty much a majority of patients that lasts
a fair bit of time. . .” made him unsure whether or not he would switch.
Logistics of product use. Items related to logistics of daily pill taking, like returning to the
clinic for checkups and refilling prescriptions at pharmacies were not associated with switch-
ing intentions. The two significant items in bivariate analysis were around the logistics of the
injections. Participants who felt more strongly that the injection interval (i.e., “I would have to
get two shots in the butt every 8–12 weeks”) was a disadvantage of the shot had lower odds of
intending to switch (OR = 0.30). The more challenging that someone rated the shot schedule
(i.e., returning to the clinic every eight to twelve weeks), the lower their odds of switching
(OR = 0.37). For example, in the words of one respondent, “Biggest drawback is that it’s a shot
and that I have to actually visit a healthcare provider to receive the dosage” (Black, 29 years
old, probably not switch).
In contrast, the following quote from the open-ended responses, illustrative of several simi-
lar quotes by definite switchers, elaborates on the idea that oral PrEP requires regular clinic
visits anyway, so that regular visits for injections were not an additional burden: “Part of the
routine of PrEP is blood work every 3 months, so a PrEP shot would fit nicely into this routine
anyway, plus alleviate any need to refill and take daily pills each month” (White, 32 year-old,
definitely switch). Others noted: “I don’t like to carry pills with me daily—its easy to forget,
especially when you lead an incredibly busy schedule” (Hispanic, 26 years old, definitely
switch). “(The shot) would make life so much easier not having to deal with pharmacies and
refills” (White, 26 years old, definitely switch).
Psychosocial motivators and barriers to switching
Psychological experience of adherence. Five out of six items that sought to measure the
psychological aspects of adhering to a daily oral pill or returning for regular clinic visits did
not show any association with intention to switch. However, despite the fact that items that
queried anxiety around missed doses did not show any associations, this theme was common
in the open-ended responses. As a 39-year-old multiracial definite switcher expressed: “I’d pre-
fer [the shot] to having to take a pill everyday and worrying about missing a dose. It would be
less stressful.”
Stronger agreement with the statement “taking PrEP pills every day feels like an emotional
burden” was associated with intention to switch (OR = 1.54). One illustrative quote captures
this notion of pill-taking as burdensome, particular when frequency of sex is inconsistent
across time:
I would probably switch. My sexual activity is sporadic, I am more focused and diligent
with taking my PrEP pills when I am sexually active regardless of if the behavior is protected
or unprotected. Sometimes I go for months without having sex or what I believe is risky
sexual exposure. PrEP seems to be a burden in the months I am not active. To take the
injection and not worry about it for months would be an ideal scenario for me, provided I
am truly confident the shot works. (Black, 53 years old, probably switch)
Agency and control. Assigning a higher score to the statement “Taking PrEP pills every
day makes me feel responsible” (OR = 1.87) was associated with higher odds of switching. This
was elaborated on in the following excerpts from responses to open-ended questions: “[PrEP]
gives you a little more confidence because mistakes happen and you have sex with someone
that you ask afterwards what their status is and knowing you aren’t just relying on them and
are taking responsibility is a good thing,” (White, 26 years old, definitely switch).
Intentions to switch from oral to injectable PrEP among oral PrEP users
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Higher scores on the statement “Not taking a pill every day would make me feel less in con-
trol of my HIV prevention” were associated with lower odds of switching (OR = 0.55). The
qualitative data elaborates on this sentiment in the following excerpt: “I also like actively taking
a pill everyday as it makes me feel more in control. I feel like I am affirming my desire to
remain HIV-free on a daily basis. Taking a shot and then forgetting about it feels sort of pas-
sive,” (Hispanic, gay, 49 years old, probably not switch). A second respondent, noted with
regards to the shot: there is a “loss of control. With the pill I know I’m actively doing some-
thing every day to protect my health. There’s much less control with a shot administered by a
doctor,” (White, 36 years old, definitely not switch).
The item that queried participants’ concern about waning protection across the injection
interval was not significant. The concern came through in several participants’ responses to
the open-ended questions. One participant articulated this with the following set of questions:
“How do we know that the 3-month injection won’t be processed out of my body at a faster
rate than the average person, thereby leaving me more vulnerable to seroconversion? What
happens to the concentration of the medication in my body as time progresses? Do I have the
same level of protection against HIV on day 90 as I do on day 1 after the shot?” (Black, 32
years old, unsure). Another noted: “I’m concerned [what] if the medicine levels will drop with-
out notice, leaving me unprotected,” (Hispanic, 25 years old, unsure). A separate measure ask-
ing about concern of not having control over starting and stopping the medication specifically
due to the long duration of protection was significant (OR = 0.56).
Early versus not early adopters. Those who rated themselves as “the kind of person who
is always first to try new something new” had higher odds of switching, compared to people
who considered themselves “slow to try new things” (OR = 2.88). “I would not want to be one
of the first people to take it. I’d want to know others who have been on it for a while. The lack
of long-term data is especially concerning,” (Hispanic, gay, 49 years old, probably not switch).
As expressed by one 26-year-old White participant (probably not switch), “I would switch
only after the long-term side effects were known. I don’t want to turn 60 and find out that I
have some rare disease because of a shot I was taking to make myself healthier years ago.”
Multivariable logistic regression model
In multivariable analysis, five predictors of intentions to switch were retained (Table 3). Two
negatively predicted switch intentions: negative ratings of product-level factors (injection
interval (aOR = 0.37) and shot schedule (aOR = 0.31)). Three psychosocial level factors posi-
tively predicted switch intentions: identifying daily pill-taking as emotionally burdensome
(aOR = 13.71), believing that PrEP signifies personal responsibility (aOR = 4.72), and self-
identifying as an early adopter (aOR = 3.77).
Discussion
This is the first study to directly ask current oral PrEP users whether they would switch to an
LAI-PrEP product, were it to become available, and probe the product-level and psychosocial
aspects of their switch intentions. As such, these experienced PrEP users offer a unique per-
spective from which to assess the pros and cons of LAI-PrEP compared to daily oral PrEP.
These men were among the earliest adopters of daily oral PrEP—enrolling into a PrEP demon-
stration within the first 24 months after FDA approval of daily oral Truvada. This makes the
beliefs and attitudes of this group of men particularly relevant to the evaluation of the pros and
cons of a new PrEP-modality, offering perspectives that are informed by the physical and psy-
chological experience of oral PrEP use.
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We developed twenty-four measures in five domains that we hypothesized would allow us
to differentiate current oral PrEP users who would be motivated to switch to injectable PrEP
from those who were likely to continue using daily oral PrEP. Measures in all five domains
showed bivariate associations and four domains retained significance in the multivariable
analysis.
Of the two product-level domains, physical experience was not, surprisingly, associated
with switching intentions. Attitudes towards pain, injections, or pill swallowing did not differ-
entiate those who had higher odds of intending to switch from those who were satisfied with
oral PrEP in the multivariable model. However, this may be because none of our quantitative
measures queried attitudes towards needles specifically, using instead, language of “shots” and
“injections.” The literature on aversion to injections and needle phobia distinguishes between
psychological concerns (fear of fainting, disgust), vasovagal concerns (fainting, loss of con-
sciousness), and needle-phobia (avoidance, distress, fear) [33, 34]. This study appears to bear
out this distinction as items eliciting reactions to injections were not associated with the out-
come, whereas many non-switchers mentioned needles as a barrier to LAI-PrEP in their open-
ended responses. Future research could use standardized scales to measure aversion to injec-
tions as compared to needles to assess whether scores on such scales could be useful in identi-
fying someone as a candidate for injectable PrEP. These data suggest that while such concerns
may not determine patient preferences, they should be discussed by providers as a critical com-
ponent of a patient’s decision-making process.
Logistical concerns mattered for participants; concerns about the frequency of injections
and clinic visits were both negatively associated with intentions to switch, whereas individuals
who were not bothered by these return visits were more likely to report wanting to switch.
Prior experiences during clinic visits for daily oral PrEP or other interactions with the health
system may predispose individuals positively or negatively towards more frequent visits for an
injectable agent. When working with patients around decision-making, providers should keep
in mind that such logistical concerns may have farther-reaching influences on patients’ daily
lives, and therefore may be more important than product-specific product factors such as con-
cerns about injections. Deepening our understanding of what is difficult about clinic visits for
injections—the frequency of visits, the lack of weekend and night-time hours at clinics, or the
intimacy of such injections—would help planning for future implementation of LAI-PrEP as
well as clinical development of future biomedical HIV prevention products.
Psychosocial-level factors also appeared to be quite important in people’s attitudes towards
LAI-PrEP. The “pro” of not needing to take a daily oral pill (i.e., adherence) has been noted as
an advantage of an LAI-PrEP modality [3, 6, 7]. However, in our data, endorsement of the
statement “not having to take a pill every day” was not significantly associated with intention
to switch, while the item “taking PrEP pills every day feels like an emotional burden” was. The
latter item captures the psychological aspect underlying the “adherence” theme—that taking a
pill every day, while doable, does take an emotional toll that seems to be operating in two ways:
for some, the act of pill-taking appears to be a reminder of the risk of HIV; for others, it high-
lights the absence of sex. While the psychological burden of pill-taking has not been previously
reported in the PrEP literature, it has been measured in the context of ARV and ARV adher-
ence [35–37]. LAI-PrEP offers an alternative that avoids the daily psychological burden of
PrEP use. Providers working with patients on decision-making may want to acknowledge the
emotional burden of pill-taking as a factor in evaluation of prevention options.
Under the theme of agency, or control, the idea that taking PrEP made users “feel responsi-
ble” was most strongly associated with switching in the multivariable model. Factors related to
a loss of control when switching from pill-taking to injectable PrEP were associated at the
bivariate level only. Mental health benefits arising from an enhanced sense of self-efficacy and
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agency among oral PrEP users have been reported elsewhere [38–44], and is conceptually
related to this finding. It is possible that patients who felt most affirmed by their oral PrEP use
were also those who were most open to trying a new approach. Focusing on taking responsibil-
ity and being in control of HIV prevention may be an important motivating factor for provid-
ers to discuss with their patients regardless of the specific modality chosen for PrEP. It is also
interesting to contrast this focus on agency with the above findings around the emotional bur-
den of pill-taking. It may be that the ways in which individuals understand and make meaning
from their PrEP behavior will be the most important factor in PrEP uptake, adherence, and
persistence across modalities.
Limitations
This study was conducted among early adopters of daily oral PrEP, which limits the generaliz-
ability of these findings to oral PrEP-experienced users. Those without experience with PrEP
may respond differently. The sample was limited to cisgender men, and more data are sorely
needed about experiences of PrEP use and PrEP preferences among cisgender women, and
transgender and non-binary individuals. It is important to note that we asked participants to
assume that insurance and financial costs of injectable PrEP would be equivalent to those they
were currently facing with daily oral PrEP; however, this may not be the case during imple-
mentation. Financial constraints may be a critical factor in determining choices among PrEP
modalities, and these should be considered in future implementation studies. In this sample,
moderate income was most strongly associated with intentions to switch; this may be a ran-
dom artifact of this particular sample, as early adoption of novel health care products and
treatment is usually associated with higher income [45–46]. Another limitation is the nature of
the qualitative data, which was derived not through interviews in which themes could be elabo-
rated through a skilled interviewer, but written responses to open-ended questions. Finally,
the wide confidence intervals around significant predictors signals the need for additional
studies to replicate these results and assess how meaningful these factors are across different
populations.
Conclusion
Psychosocial factors appear to motivate intentions to switch to injectable PrEP among expe-
rienced PrEP users. In anticipation of the availability of a LAI-PrEP product, there is a need
for rigorous behavioral and social science research to inform the development of tools to
support decision-making around PrEP modalities that take into account the psychosocial
factors identified in this study. Such factors—especially issues around the meaning of pill-
taking for patients as an emotional burden versus a symbol of agency and control—will be
critical to the development of patient education materials and shared decision-making pro-
cesses with providers.
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